Literature DB >> 9925243

What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)?

F Stewart1, P Baas, W Star.   

Abstract

Major advances have recently been made in photodynamic therapy (PDT) for clinical application, including the development of more powerful photosensitizers and light sources and suitable light applicators. PDT is emerging as an attractive new form of cancer therapy, suitable for treating superficial lesions (less than 1 cm in depth) and carcinoma in situ, or as an adjuvant to surgery for more bulky disease. PDT is therefore complementary to radiotherapy which is better suited to treating larger tumours. There are some qualitative similarities between light distribution in tissue during superficial illumination and ionizing radiation dose distributions during external beam irradiation, or between interstitial PDT and brachytherapy, although the geometric scale is very different (visible light penetrates a maximum of 5-10 mm in tissue). The contribution of scattered light to tissue irradiance is much greater than for ionizing radiation and in situ light dosimetry is very important (although rather complicated) to ensure adequate illumination without over-treating. Dosimetry and treatment planning are highly advanced for ionizing radiation and are routine in all radiotherapy departments. Proper in situ light dosimetry and dose distribution calculation for PDT is in its infancy. Physicists have an important role to play in the further optimization of clinical PDT and much of the infrastructure and expertise present in the radiotherapy department is ideally suited to accommodate PDT. In this review, parallels and contrasts are made between PDT and ionizing radiation for both mechanistic and dosimetric aspects of the therapies. A summary of the most interesting clinical applications is also given.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9925243     DOI: 10.1016/s0167-8140(98)00063-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Mitochondrial effects of triarylmethane dyes.

Authors:  A J Kowaltowski; J Turin; G L Indig; A E Vercesi
Journal:  J Bioenerg Biomembr       Date:  1999-12       Impact factor: 2.945

2.  Harnessing the Power of Nanotechnology for Enhanced Radiation Therapy.

Authors:  Shreya Goel; Dalong Ni; Weibo Cai
Journal:  ACS Nano       Date:  2017-06-16       Impact factor: 15.881

3.  Photocytotoxic trans-diam(m)ine platinum(IV) diazido complexes more potent than their cis isomers.

Authors:  Nicola J Farrer; Julie A Woods; Vivienne P Munk; Fiona S Mackay; Peter J Sadler
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

4.  Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer. A case report.

Authors:  M Schaffer; A Hofstetter; B Ertl-Wagner; R Batash; J Pöschl; P M Schaffer
Journal:  Strahlenther Onkol       Date:  2013-10-26       Impact factor: 3.621

5.  Enhanced Efficacy of Photodynamic Therapy by Coupling a Cell-Penetrating Peptide with Methylene Blue.

Authors:  Jinhui Ser; Ji Yeon Lee; Yong Ho Kim; Hoonsung Cho
Journal:  Int J Nanomedicine       Date:  2020-08-06

6.  The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid--a study on normal rat colon.

Authors:  A Curnow; S G Bown
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

7.  Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid.

Authors:  M J Niedre; C S Yu; M S Patterson; B C Wilson
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.